Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus.

Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis[1] and of methicillin-resistant S.

[3] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.